Rasagiline

K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released August 9, 2005; last updated August 1, 2017; expires August 1, 2020

Historical note and terminology

Monoamine oxidase inhibitors were considered potentially useful in the treatment of Parkinson disease, as blocking its breakdown could enhance dopamine transmission. However, nonselective monoamine oxidase inhibitors did not prove beneficial when given as monotherapy, and hypertensive crises were a problem. It was then discovered that selegiline, as a selective monoamine oxidase type B inhibitor, did not produce this reaction and was the first product in this category to be approved for the treatment of Parkinson disease. Rasagiline is a potent, second-generation, selective, irreversible monoamine oxidase type B inhibitor. Unlike selegiline, a drug for Parkinson disease with a similar mechanism of action, rasagiline is not metabolized to amphetamine derivatives. On February 22, 2005, the European Commission gave the final marketing authorization for rasagiline for the treatment of Parkinson disease. It is marketed in Europe as Azilect. It was approved by the FDA in the United States on May 17, 2006.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.